QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.087643v1 315/2/545    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furutani, T. Articles by Kato, S. Search for Related Content PubMed PubMed Citation Articles by Furutani, T. Articles by Kato, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Degenerative Nerve Diseases Genetics Home Reference

NEUROPHARMACOLOGY

Human Expanded Polyglutamine Androgen Receptor Mutants in Neurodegeneration as a Novel Ligand Target

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan (T.F., H.K., N.T., M.K., M.S., H.S.); Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo, Japan (K.-I.T., M.T., S.I., E.S., S.K.); and Exploratory Research for Advanced Technology, Japan Science and Technology, Kawaguchi, Saitama, Japan (S.K.)

Androgen receptor (AR) plays key roles in various biological events, including pathological processes such as prostate cancer, androgen-insensitive syndrome, and spinal and bulbar muscular atrophy (SBMA). SBMA is caused by mutation of the expanded polyglutamine (polyQ) stretches in the AR gene. Recently, we established a Drosophila SBMA model that expresses the expanded polyQ hAR mutant in eyes, which monitors neurodegeneration as a rough eye phenotype. In addition, we showed that androgen binding to the mutant hAR causes structural alterations, leading to the onset of neurodegeneration in the fly eyes. In the present study, we examined whether the ligand-induced neurodegeneration via the hAR mutant is coupled with the known ligand-induced transactivation function of hAR. By testing several known AR antagonists and several of their structure-related compounds, we unexpectedly found that none of the AR ligands antagonized the hAR mutant neurodegeneration function, and surprisingly, compound 4-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)-2-trifluoromethylbenzonitrile (RU56279) was more potent in inducing neurodegeneration. However, in vitro and in vivo mammalian assays showed that RU56279 exhibited the expected antagonistic activity with the same potency as those of the other compounds. Thus, these findings suggest the presence of a novel ligand-induced function of the polyQ hAR mutant in neurodegeneration that could not be prevented by known antagonists for the hAR transactivation function.

Address correspondence to: Shigeaki Kato, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo 113-0032, Japan. E-mail: uskato{at}mail.ecc.u-tokyo.ac.jp

This article has been cited by other articles:

				H. L. Montie, M. S. Cho, L. Holder, Y. Liu, A. S. Tsvetkov, S. Finkbeiner, and D. E. Merry Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy Hum. Mol. Genet., June 1, 2009; 18(11): 1937 - 1950. [Abstract] [Full Text] [PDF]